References
- McLean A J, Harrison P M, Ioannides-Demos L, Byrne A J, McCarthy P, Dudley F J. The choice of ulcer healing agent influences duodenal ulcer relapse rate and long-term clinical outcome. Aust NZ Med 1985; 15: 367–374
- Wagstaff A J, Benfield P, Monk J P. Colloidal bismuth subcitrate: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease. Drug Evaluation 1988; 36: 132–157
- Bianchi Porro G, Lazzaroni M, Barbara L, et al. Tripotassium dicitrate bismuthate and ranitidine in duodenal ulcer. Scand J Gastroenterol 1988; 23: 1232–1236
- Lee F J, Samloff L, Hardman M. Comparison of tripotassium di-citrato bismuthate tablets with ranitidine in healing and relapse of duodenal ulcers. Lancet 1985; 1: 1299–1302
- Martin D F, May S J, Tweedle D E, Hollanders D, Ravenscroft M M, Miller J P. Difference in relapse rates of duodenal ulcer after healing with cimetidine or tripotassium dicitrato bismuthate. Lancet 1981; 1: 7–10
- Hamilton I, O'Connor H J, Wood N C, Bradbury I, Axon A T R. Healing and recurrence of duodenal ulcer after treatment with tripotassium dicitrato bismuthate (TDB) tablets or cimetidine. Gut 1986; 27: 106–110
- Miller J P. Colloidal bismuth in the treatment of duodenal ulceration: the benefit for the patient. Scand J Gastroenterol 1989; 24(suppl 157)16–20
- Miller J P, Faragher E B. Relapse of duodenal ulcer: does it matter which drug is used in initial treatment?. Br Med J 1986; 293: 1117–1118
- McLean A J, Harcourt D M, McCarthy P G, Dudley F J, McNeil J J. Relative effectiveness and costs of antiulcer medications as a basis for rational prescribing. Med J Aust 1987; 146: 431–439
- Lane M R, Lee S P. Recurrence of duodenal ulcer after medical treatment. Lancet 1988; 1: 1147–1149
- Jensen D M. Economic and health aspects of peptic ulcer disease and H2-receptor antagonists. Am J Med 1986; 81(suppl 4B)42–48
- Culyer A J, Maynard A K. Cost-effectiveness of duodenal ulcer treatment. Soc Sci Med 1981; 15C: 3–11
- Drummond M F, Stoddart G L, Torrance G W. Methods for the economic evaluation of health care programmes. Oxford University Press, Oxford 1987
- Ward M. The management of the patient with peptic ulceration—an update. Aust Fam Physician 1987; 16: 383–390
- Newethicalscatalogue. Adis Press, Ltd., AucklandNew Zealand 1989
- Bresci G, Capria A, Federici G, Rindi G, Geloni M, Corsini G. Prevention of relapse with various antiulcer drugs. Scand J Gastroenterol 1986; 21(suppl 121)58–62
- Smith A C, Price A B, Borriello P, Levi A J. A comparison of ranitidine and tripotassium dicitrato-bis-muth (TDB) in relapse rates of duodenal ulcer. The role of campylobacter pylori (CP) ‘Abstract’. Gastroenterology 1988; 94: A431
- Walan A, Bianchi Porro G, Hentschel E, Bardhan K D, Delattre M. Maintenance treatment with cime-tidine in peptic ulcer disease for up to 4 years. Scand J Gastroenterol 1987; 22: 397–405
- Bardhan K D, Hinchcliffe R F C, Bose K. Low dose maintenance treatment with cimetidine in duodenal ulcer; intermediate-term results. Postgrad Med J 1986; 62: 347–351
- Gough K R, Bardhan K D, Crowe J P, Korman M G, Lee F I, Reed P I. Ranitidine and cimetidine in prevention of duodenal ulcer relapse. Lancet 1984; 2: 659–662
- Bardhan K D. Intermittent treatment of duodenal ulcer for long term medical management. Postgrad Med J 1988; 64(suppl 1)40–46
- Boyd E J S, Penston J G, Johnston D A, Wormsley K G. Does maintenance therapy keep duodenal ulcers healed?. Lancet 1988; 1: 1324–1327
- Tytgat G N J. Collodial bismuth subcitrate in peptic ulcer—a review. Digestion 1987; 37(suppl 2)31–31
- Smith A. The appraisal of health service capital schemes. Department of Health, Management Services and Research Unit, Wellington 1983, special report no. 65
- Key statistics. Department of Statistics. October, 1989
- Automobile Association of New Zealand. November, 1989